Call for Abstract
1 st International Conference on Clinical Ophthalmology and Oculoplastic Surgery, will be organized around the theme “Advances in Oculoplastic Surgery”
Oculoplastic Surgery 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Oculoplastic Surgery 2018
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Oculoplastic surgery largely consists of traditional approaches to many of the encountered diseases. Our specialty has well-established methods for most surgeries and we use our good old fashioned surgical instruments, but advances are continuously being made to improve patient outcomes while at the same time abiding by sound surgical and medical principles according to anatomy. These advances are made in both surgical and non-surgical approaches to functional and aesthetic oculoplastic surgery. There has been a lot of excitement in ocuplastic surgery recently. New surgical techniques, many of which are less invasive, new cosmetic tools with particular utility around the eyes, and new team approaches have fueled the excitement. The aging baby boomer population has increased demand for cosmetic procedures; the ability to work outside the traditional insurance system has added momentum to the interest and curiosity of ophthalmologists. Indeed the accreditation given to American Society of Ophthalmic Plastic and Reconstructive Surgery by the Accreditation Council for Graduate Medical Education will ignite the debate over sub-specialty board certification for ophthalmic plastic surgery.
- Track 1-1Blepharoplasty
- Track 1-2Epicanthoplasty
- Track 1-3Lateral Canthoplasty
- Track 1-4Brow lift surgery
Clinical Ophthalmology will enhance your knowledge of common ocular diseases, ophthalmic surgical and laser procedures, clinical anatomy and ocular therapeutics. You will develop analytical skills for solving clinical case problems and evaluating published research, and gain valuable research experience through the opportunity.
- Track 2-1 Ocular Refraction and Therapeutics
- Track 2-2Community Ophthalmology
- Track 2-3Eye and Surrounding Disorders
- Track 2-4Retina and Retinal Disorders
- Track 2-5Cornea and Corneal Diseases
- Track 2-6Lens Disorders
Pediatric ophthalmology is a sub-speciality of ophthalmology concerned with eye diseases, visual development, and vision care in children. The pediatric ophthalmologist has additional training, experience, and expertise in examining children, and has the greatest knowledge of possible conditions that affect the pediatric patient and his/her eyes. Neurologic development of vision occurs up until approximately age 12 years. Misalignment of the eyes (strabismus), uncorrected refractive error (myopia, hyperopia, and astigmatism), and asymmetry of refractive error between the two eyes can negatively affect this development. If these conditions are diagnosed and treated early, good vision can develop and can be maintained. Certain diseases elsewhere in the body, such as diabetes, can affect the eyes, and the pediatric ophthalmologist addresses these, as well.
- Track 3-1Retinopathy of Prematurity
- Track 3-2Eye Screening
- Track 3-3Strabismus
- Track 3-4Amblyopia, Exotropia, Esotropia
- Track 3-5Superior Oblique Palsy
- Track 3-6Retinoblastoma
- Track 3-7Thyroid Eye Disease
- Track 3-8Dissociated Vertical Deviation (DVD)
Glaucoma is a multifactorial optic neuropathy that affects more than 50 million people and is the second leading cause of blindness worldwide. The role of intra ocular pressure (IOP) has been well documented as a major modifiable risk factor for glaucoma. Additionally, many glaucoma patients have a relatively low IOP, while some healthy individuals have a relatively high IOP. The disorders can be roughly divided into two main categories, open-angle glaucoma and closed-angle glaucoma. Impaired ocular blood flow regulation in open angle glaucoma as a risk of glaucoma has also been well established, especially over the past two decades. Pathophysiology of glaucoma indicates towards the increased in intraocular pressure which compresses and damages the optic nerve. Once the optic nerve is damaged, it fails to carry visual information to the brain and this result in loss of vision. The exact pathophysiology of glaucoma contributing to this is yet to be determined. Biomarkers for glaucoma have predictive use that could help and guide more specific therapy in some glaucoma patients. Endothelin in glaucoma treatment play a very key role in pathogenesis of glaucoma. Glaucoma accounts for over 10 million visits to physicians each year. In terms of Social Security benefits, lost income tax revenues, and health care expenditures, the cost to the U.S. government is estimated to be over $1.5 billion annually. The Glaucoma Research Society of Canada is the only Canadian non-profit organization solely dedicated to funding glaucoma research. Since 1989, it has raised more than two million dollars in support of 150 research projects. The Society funds 10 to 15% of all independent glaucoma research in Canada. Bascom Palmer and Wills Eye are the top researcher organization for glaucoma.
- Track 4-1Pathophysiology of Glaucoma
- Track 4-2Open-angle Glaucoma
- Track 4-3Biomarkers for Glaucoma
- Track 4-4Impaired ocular blood flow regulation in open angle Glaucoma
- Track 4-5Endothelin in Glaucoma treatment
- Track 4-6Complications and Management of Glaucoma Filtering
- Track 4-7Closed-angle Glaucoma
The retina is a thin layer of tissue on the inside back wall of your eye. It contains millions of light-sensitive cells and other nerve cells that receive and organize visual information. Your retina sends this information to your brain through your optic nerve, enabling you to see. Retinal degenerative disorders such as Age-related macular degeneration and Myopic macular degeneration affecting young and old from many cultures, races and ethnicities. The central area of the retina contains a high density of color-sensitive photoreceptor cells called cones which are responsible for color vision and hence any defect and alteration in the central area of the retina will lead to Color vision defects. On the other hand diseases like Diabetic retinopathy and Retinal tumors can also be responsible for the permanent vision loss if it is not treated on time. Historically, retinal disease has had a low priority in prevention of blindness programs in developing countries. There are several reasons for this. Firstly, it was thought that retinal disease was an uncommon cause of blindness in the developing world; secondly, that the results of treating retinal disease did not justify the effort and expense involved; and, thirdly, that the equipment required was too costly and unreliable for use in a developing country environment. Finally, there is a lack of skilled personnel with sub-specialty training in retinal disease. John Hopkins School of Medicine, UCSF School of Medicine, David Geffen School of Medicine and Mayo Medical School are the leading institutes associates with ophthalmology.
- Track 5-1Age-related macular degeneration
- Track 5-2Myopic macular degeneration
- Track 5-3Diabetic retinopathy
- Track 5-4Color vision defects
- Track 5-5Retinal tumors
- Track 5-6Retinal artery occlusion
- Track 5-7Retinal vein occlusion
- Track 5-8Retinal Detachment
- Track 5-9Hemoglobinopathy Retinopathy
- Track 5-10Choroidal Neovascularization
- Track 5-11Retinopathy of Prematurity Ophthalmologic Approach
Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, called the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, leading to permanent vision loss.
- Track 6-1Anterior uveitis
- Track 6-2Intermediate uveitis
- Track 6-3Posterior uveitis
Strabismus is a vision problem in which both eyes do not look at the same point at the same time. Strabismus most often begins in early childhood. It is sometimes called crossed-eyes, walleye or squint. Strabismus can be treated surgically or non-surgically. This condition is ideally treated as early as possible (particularly in children) so that it does not progress to require extensive corrections. There are a number of non-surgical treatments for strabismus, all of which put the weaker eye to use in order to strengthen it.
- Track 7-1Psychosocial effects
- Track 7-2Diagnosis
External eye disease encompasses a very diverse range of conditions. At one end of the spectrum, it includes conditions which form the “bread and butter” of general or primary care ophthalmology, whilst at the opposite end of the spectrum it includes some conditions which may require very complex surgical or systemic treatment.
- Track 8-1Conjunctivitis
- Track 8-2Styes
- Track 8-3Keratoconus
- Track 8-4Corneal dystrophies
- Track 8-5Genetic cornea diseases
- Track 8-6Itchy eyes
- Track 8-7Soft contact lens
- Track 8-8Devices used in optometry
Optometry is a social insurance calling that practices on the eyes and related structures, and vision, visual frameworks, and vision data handling in people. Optometrists (otherwise called Doctors of Optometry or Ophthalmic Opticians relying upon the nation) are prepared to endorse and fit focal points to enhance vision, and in a few nations are prepared to analyse and treat different eye sicknesses. Optometric doctors and optometry-related associations communicate with legislative offices, other social insurance experts, and the group to convey eye-and vision-care.
- Track 9-1Diagnosis and assessment of keratoconus
- Track 9-2Contact lens related conditions in cornea
- Track 9-3Ocular pathologies related to contact lens use
- Track 9-4Orthokeratology lenses and contact fitting
- Track 9-5Low vision
- Track 9-6Ocular mobility
Ophthalmic pathology focuses on diseases of the eye and its neighboring tissues. Precision diagnosis of diseases is provided by the ophthalmic pathology service. Diseased tissues are examined macroscopically, microscopically and on the ultrastructural level. Advanced genomic, proteomic, and cytogenetic techniques can be utilized to diagnose diseases at a molecular level. The pathologic diagnosis of the disease plays a vital role in patient care. Ophthalmic pathology is a laboratory-based discipline which provides an essential service to ophthalmologists and related professionals by examining samples taken from patients in order to provide a diagnostic opinion.
- Track 10-1Antibody-dependent & antibody-mediated diseases
- Track 10-2Cell-mediated diseases
- Track 10-3Corneal graft reactions
- Track 10-4Fungal endophthalmitis
- Track 10-5Antibiotics in ocular infections
- Track 10-6Recent developments in pathology & immunotherapy
Ophthalmic Pharmacology is the study and utilization of medications to both analyze and treat ailments of the eye. There are different microbial maladies of the eye like Fungal contaminations of the cornea, which are uncommon yet may happen after agrarian wounds or in hot and moist atmospheres, orbital mycosis is even rarer, and for the most part happens after spread from the paranasal sinuses. Expanding age, debility, or immunosuppression improves probability and seriousness of illness.
- Track 11-1Pharmacologic principles
- Track 11-2Drugs and the eye
- Track 11-3Ocular medication
- Track 11-4Pharmacotherapy of glaucoma
- Track 11-5Agonists and blockers in ophthalmology
Ophthalmic Oncology is a highly specialized and niche facility offering expert care in the treatment various cancerous tumours of the eye and surrounding structures. The commonest tumour of the eye occurs in children and is called ‘Retinoblastoma’. The second most common intra-ocular tumour treated is Choroidal Melanoma which largely occurs among adults; it has advance facilities and expertise in procedures such as Transpupillary Thermo Therapy, Brachytherapy, Local Tumour Resection in the form of Eye Wall Resection for effectively treating this condition.
- Track 12-1Tumors of eyelids
- Track 12-2Eyelid lumps and bumps
- Track 12-3Diagnosis and treatment
- Track 12-4Retinoblastoma and neoplasms
- Track 12-5Melanoma in eye
- Track 12-6Psychological needs and communication for eye cancer patients
Translational Ophthalmology is a latest trend that bridges the gap by achieving breakthrough discoveries to patients faster than ever. Translational Research is a new initiative of the National Institutes of Health (NIH) which aims to translate basic research into more advanced form to yield the better results. The research trend discoveries maximize the opportunities to investigate the issues very minutely to decrease the risk of failure especially during surgical procedure like cataract and refractive surgery. Many fruitful facts have been discovered which indirectly helps in treating the respective conditions such as Age-Related Eye Disease Study (AREDS) proved that nutritional supplements (nutrition and ophthalmology) could minimize the risk of AMD. The American Health Assistance Foundation, dedicated to eradicating age-related degenerative diseases, estimates that up to 11 million people in the United States have some form of AMD - a number expected to double by 2050. Estimates of the global cost of visual impairment AMD causes are $343 billion, including $255 billion in direct health care costs, according to the foundation. Ophthalmology represents 18 percent of the average case volume in surgery centers, second behind GI/endoscopy (25 percent). The average surgery center performs 4,869 cases annually, which would average to around 876 ophthalmology cases annually, according to VMG Health's 2009 Intellimarker.
- Track 13-1Strabismus Surgery
- Track 13-2Glaucoma Surgery
- Track 13-3Cataract and Refractive Surgery
- Track 13-4Retinal Detachment Surgery
- Track 13-5Vision Correction Surgery
- Track 13-6Ophthalmology Surgical Instruments
- Track 13-7Eye Surgery Updates
- Track 13-8Oculoplastic Surgery
Oculoplastic and lacrimal surgery is a sub-strength of ophthalmology which concentrates on disarranges of the eyelids, tear-seepage framework and the bones behind the eye, generally known as the circle. Oculoplastic surgery likewise incorporates restorative surgery of the eyes. Regular issues that require Oculoplastic, lacrimal or orbital surgery include: Facial breaks and wounds, Tumors, Droopy eyelids, Blocked tear pipes, Skin malignancy, Birth deformations, Thyroid eye disease, Excessive watering of the eye.
- Track 14-1All molecular diseases
- Track 14-2Eye and orbit ultrasounds
- Track 14-3Apraxia
- Track 14-4Clinical cases with practical pearls
- Track 14-5Eyelid and lacrimal disorders
- Track 14-6Surgical procedures
- Track 14-7Innovations in oculoplastic & lacrimal surgery
Imaging of the eye is critical to improving the diagnosis, assessment of severity and progression, and evaluation of management of eye disease. Advances have been rapid, with improvements in hardware (such as light sources and imaging chips), optics (such as adaptive aberration compensation) and software (such as image tracking). Imaging of the eye allows changes in its anatomy and physiology to be observed and assessed. Although great advances have been made in imaging chip technology (which has enhanced slit-lamp and fundus photography), imaging of the eye can also be achieved using reconstructed images.
- Track 15-1ocular imaging devices
- Track 15-2Optical coherence tomography
- Track 15-3scanning laser ophthalmoscopy
- Track 15-4scanning laser polarimetry
- Track 16-1Toxic amblyopia
- Track 16-2Optic neuritis
- Track 16-3Astigmatism
- Track 16-4Conjunctivitis and allergies
- Track 16-5Glaucoma
- Track 16-6Cataract
- Track 16-7Diabetic retinopathy
- Track 16-8Lazy eye and turner syndrome
Advances in ophthalmic drug delivery systems such as Punctal Plugs, Ocular Therapeutix, Mati therapeutics (QLT) and gel-forming drops can be breakthrough in ophthalmic research and advance drug delivery system to maximize the therapeutic effect of a particular drug. Topical combination of corticosteroid & anti-infective agents, Drugs used in the treatment of allergic conjunctivitis, Oral & topical nonsteroidal anti-inflammatory agents (NSAIDs) and Retinoblastoma chemotherapy are few developed formulation to treat ophthalmic diseases. Companies like Allergan, Pfizer, Bausch + Lomb, Merck & Co. and Regeneron are actively participated in ophthalmic research and drug development. According to visiongain (Ophthalmic Drugs: World Market Prospects - 2013-2023; October 2013), the worldwide ophthalmic market was $17.5 billion in 2011 and is expected to grow to $34.7 billion by 2023, representing a 5.9% compounded annual growth rate.
- Track 17-1IVT injection-sparing approaches
- Track 17-2Diagnostic dye solutions
- Track 17-3Oral & topical nonsteroidal anti-inflammatory agents (NSAIDs)
- Track 17-4Drugs used in the treatment of allergic conjunctivitis
- Track 17-5Transplantation technologies for retinal
- Track 17-6Topical combination corticosteroid & anti-infective agents
- Track 17-7Advances in ophthalmic drug delivery systems
- Track 17-8Sustained delivery approaches
- Track 17-9Extended activity approaches
- Track 17-10Ocular & systemic side effects of drugs